» Articles » PMID: 25657041

Multiphasic Changes in Systemic VEGF Following Intravitreal Injections of Ranibizumab in a Child

Overview
Journal Eye (Lond)
Specialty Ophthalmology
Date 2015 Feb 7
PMID 25657041
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To investigate whether intravitreal ranibizumab injections administered to a child alter systemic plasma levels of total and free VEGF 165.

Methods: A 9-year-old child sustained a choroidal rupture from blunt trauma. He subsequently developed a secondary choroidal neovascular membrane, which was treated with five ranibizumab injections over a period of 8 months. Peripheral venous blood samples were taken at each visit over a period of 12 months and plasma was extracted. Plasma VEGF 165 levels were determined using enzyme-linked immunosorbent assay and were assayed both pre- and post-immunodepletion to remove complexed VEGF.

Results: Plasma VEGF 165 levels proved labile following intravitreal injection of ranibizumab. Levels increased by 30% above baseline following the first intravitreal ranibizumab injection, but then returned to baseline despite two subsequent injections. There was then a rebound increase of 67% in total plasma VEGF levels following a further injection, which remained above baseline for 12 weeks despite two further intravitreal ranibizumab injections. Baseline levels were re-attained 26 weeks after the final injection.

Conclusions: These results suggest intravitreal ranibizumab injections can cause significant, multiphasic changes in systemic VEGF levels. This may be of particular clinical significance in children as VEGF is known to be vital in the development of major organs, in addition to its role in the maintenance of normal organ function in adults.

Citing Articles

The association between intravitreal ranibizumab therapy and serum cytokine concentrations in patients with diabetic macular edema.

Gnanasekaran S, Bandala-Sanchez E, Kolic M, Churilov L, Rogers S, McAuley A Mol Vis. 2020; 26:246-256.

PMID: 32256028 PMC: 7127926.


A novel anti-TNF scFv constructed with human antibody frameworks and antagonistic peptides.

Geng S, Chang H, Qin W, Lv M, Li Y, Feng J Immunol Res. 2015; 62(3):377-85.

PMID: 26059602 DOI: 10.1007/s12026-015-8667-8.

References
1.
Chakravarthy U, Harding S, Rogers C, Downes S, Lotery A, Wordsworth S . Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012; 119(7):1399-411. DOI: 10.1016/j.ophtha.2012.04.015. View

2.
Klein R, Zinman B, Gardiner R, Suissa S, Donnelly S, Sinaiko A . The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients: the Renin-Angiotensin System Study. Diabetes. 2005; 54(2):527-33. DOI: 10.2337/diabetes.54.2.527. View

3.
Segerstrom L, Fuchs D, Backman U, Holmquist K, Christofferson R, Azarbayjani F . The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. Pediatr Res. 2006; 60(5):576-81. DOI: 10.1203/01.pdr.0000242494.94000.52. View

4.
Bocci G, Man S, Green S, Francia G, Ebos J, du Manoir J . Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res. 2004; 64(18):6616-25. DOI: 10.1158/0008-5472.CAN-04-0401. View

5.
Zhu X, Chade A, Rodriguez-Porcel M, Bentley M, Ritman E, Lerman A . Cortical microvascular remodeling in the stenotic kidney: role of increased oxidative stress. Arterioscler Thromb Vasc Biol. 2004; 24(10):1854-9. DOI: 10.1161/01.ATV.0000142443.52606.81. View